rs864309504
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM2PP2PP3_ModeratePP5_Very_Strong
The NM_001303256.3(MORC2):c.260C>T(p.Ser87Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_001303256.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MORC2 | ENST00000397641.8 | c.260C>T | p.Ser87Leu | missense_variant | Exon 5 of 26 | 5 | NM_001303256.3 | ENSP00000380763.2 | ||
MORC2 | ENST00000215862.8 | c.74C>T | p.Ser25Leu | missense_variant | Exon 6 of 27 | 1 | ENSP00000215862.4 | |||
MORC2 | ENST00000476152.2 | n.382C>T | non_coding_transcript_exon_variant | Exon 4 of 7 | 5 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Charcot-Marie-Tooth disease axonal type 2Z Pathogenic:4
For these reasons, this variant has been classified as Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MORC2 protein function. ClinVar contains an entry for this variant (Variation ID: 218308). This missense change has been observed in individual(s) with Charcot-Marie-Tooth disease type 2 (CMT2) (PMID: 26497905, 27105897). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 87 of the MORC2 protein (p.Ser87Leu). -
The observed missense c.260C>T(p.Ser87Leu) variant in MORC2 gene has been reported previously in multiple individuals affected with Charcot-Marie-Tooth disease (Duan X, et al., 2021; Guillen Sacoto MJ, et al., 2020; Hyun YS, et al., 2016). Functional studies indicate that this variant significantly reduces MORC2 ATPase activity and demonstrates a damaging effect (Sancho P, et al., 2019; Douse CH, et al., 2018). The p.Ser87Leu variant is absent in gnomAD Exomes. This variant has been submitted to the ClinVar database as Uncertain Significance / Pathogenic (multiple submissions). The amino acid change p.Ser87Leu in MORC2 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. The amino acid Ser at position 87 is changed to a Leu changing protein sequence and it might alter its composition and physico-chemical properties. For these reasons, this variant has been classified as Pathogenic. -
- -
Same nucleotide change resulting in same amino acid change has been previously reported as de novoo and observed in at least two similarly affected unrelated individuals (PMID:26497905, 27105897, PS2, PS4_M). The variant was observed as assumed (i.e. paternity and maternity not confirmed) de novoo (3billion dataset, PM6). It is not observed in the gnomAD v2.1.1 dataset (PM2). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.816, 3Cnet: 0.757, PP3). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. -
Global developmental delay Pathogenic:1
- -
Inborn genetic diseases Pathogenic:1
The p.S87L pathogenic mutation (also known as c.260C>T), located in coding exon 5 of the MORC2 gene, results from a C to T substitution at nucleotide position 260. The serine at codon 87 is replaced by leucine, an amino acid with dissimilar properties. This variant has been detected as de novo in multiple individuals with Charcot-Marie-Tooth disease type 2 (Hyun YS et al. Brain, 2016 07;139:e40; Sevilla T et al. Brain, 2016 Jan;139:62-72; Duan X et al. Orphanet J Rare Dis, 2021 05;16:244; Guillen Sacoto MJ et al. Am J Hum Genet, 2020 08;107:352-363). This alteration is located in the ATPase domain and is reported to result in reduced ATPase activity and abnormal N-terminal dimerization dynamics in human cell lines (Sancho P et al. Hum Mol Genet, 2019 05;28:1629-1644; Douse CH et al. Nat Commun, 2018 02;9:651). In addition, this variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
not provided Pathogenic:1
Published functional studies demonstrate a damaging effect (PMID: 29440755); Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 34189813, 26497905, 27105897, 28135719, 31211173, 30624633, 32693025, 34059105, 31785789, 33762496, 29440755) -
Developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy Pathogenic:1
Variant c.260C>T in MORC2 was found in a Patient with clinical signs of DIFGAN syndrome. Segregation analysis confirmed its de novo. This variant is absent in population databases. For functional characterization of the variant a vector, expressing MORC2 fused with Flag tag at C-terminal end, was created. Transfection of the plasmid into HEK293T cells followed by Western blotting revealed significant reduction of MORC2 protein quantity compared to wt vector. In summary, c.260C>T variant meets criteria to be classified as pathogenic. -
Charcot-Marie-Tooth disease Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at